These findings suggest that CD33’s influence on neurocognitive decline may extend beyond neurodegenerative diseases such as Alzheimer’s disease to potentially include viral hepatitis. This evidence concerns the gene CD33 and early-onset autosomal dominant Alzheimer disease.